English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers of the University of Bristol-led study, published in Science Advances today [23 November], say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses.
Tag: SARS-CoV
Texas Biomed and partners discover new, potent COVID-19 antibody cocktail
Researchers at Texas Biomed and University of Alabama at Birmingham discovered an antibody cocktail against COVID-19 that appears effective against all variants and other coronaviruses. The cocktail has been exclusively licensed to Aridis Pharmaceuticals, which is seeking a manufacturing partner to advance the treatment to human clinical trials.
Cormac the Llama Yields Antibodies that may Prove Effective Against COVID-19 Infection
Researchers from the Uniformed Services University (USU) recently identified pint-sized antibodies, or “nanobodies,” that could protect against COVID-19. At least one of these nanobodies – produced by a llama named Cormac – also appears to work well in either liquid or aerosol form, suggesting it could also help protect a person’s lungs from infections.
Amount of COVID Viral RNA Detected at Hospital Admission Predicts How Patients Will Fare
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19. SARS-CoV-2 is the virus that causes COVID-19. Previous studies on this question have had conflicting results.
UNH Digs Deep Testing Wastewater for Early Warning Signs of COVID-19
The University of New Hampshire has gone underground to flush out cases of the coronavirus by testing wastewater on campus. The sewage sampling is being used as a secondary surveillance method to the already required twice a week individual nasal test to track and detect SARS-CoV-2, the virus that causes COVID-19.
COVID-19 Frequently Causes Neurological Injuries
Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows. These injuries range from temporary confusion due to low body-oxygen levels, to stroke and seizures in the most serious cases, say the study authors.
Baylor Scott & White Health Enrolls First Patients in the World in Trial for Inhaled Remdesivir
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
COVID-19 Appears Less Severe in Children, Says Review in Pediatric Infectious Disease Journal
As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there’s reassuring evidence that children have fewer symptoms and less severe disease. That’s among the insights provided by an expert review in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
COVID-19 Appears Less Severe in Children, Says Review in Pediatric Infectious Disease Journal
As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there’s reassuring evidence that children have fewer symptoms and less severe disease. That’s among the insights provided by an expert review in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.